Ritipenem acoxil, a new oral penem antibiotic, in urogenital infection

The following results were obtained for a new oral penem antibiotic, ritipenem acoxil (RIPMAC). 1. Diffusion into human prostatic fluid The concentration of ritipenem (RIPM) in the prostatic fluid at 1 hour after administration of 400 mg RIPM-AC was less than 0.08 μg/ml in all of 4 human prostatic fluid specimens tested. 2. Clinical study on UTI The drug was given at daily doses of 450-600 mg divided into 3 times, for a period of 3-7 days in 24 patients with UTI. According to the Japanese UTI Committee's criteria, the efficacy on 17 patients with chronic complicated urinary tract infection was excellent in 11 patients, moderate in 4 and poor in 2, thus, a response rate being 88.2%. As for side effect, stomach discomfort was found in one patient. There were no particular significant abnormal laboratory values.